Skip to main content
SpringerLink
Log in
Book cover

Immune Mediators in Cancer pp 15–28Cite as

Analysis of Circulating HMGB1 in Human Serum

  • Protocol
  • First Online:

Part of the book series: Methods in Molecular Biology ((MIMB,volume 2108))

Abstract

As a ubiquitous nuclear protein, high-mobility group box 1 (HMGB1) is constitutively expressed and can be actively secreted by macrophages/monocytes, as well as passively released from damaged cells following pathological injuries. Studies indicate that HMGB1 functions as a mediator of infection- and injury-elicited inflammatory diseases. Although intracellular HMGB1 functions as a regulator of tumorigenesis, epigenetic anticancer agents or therapeutic γ-ray irradiation could also cause active secretion or passive release of HMGB1, enabling serum HMGB1 to serve as a biomarker for the diagnosis and therapy of various cancers. Here we describe a semiquantitative immune blotting method to measure HMGB1 in human serum, in comparison with a commercially available HMGB1 enzyme-linked immunosorbent assay (ELISA) technique.

This is a preview of subscription content, log in via an institution.

Protocol
USD   49.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   99.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   129.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   199.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Springer Nature is developing a new tool to find and evaluate Protocols. Learn more

References

  1. Wang H, Bloom O, Zhang M et al (1999) HMG-1 as a late mediator of endotoxin lethality in mice. Science 285:248–251

    Article  CAS  PubMed  Google Scholar 

  2. Bonaldi T, Talamo F, Scaffidi P et al (2003) Monocytic cells hyperacetylate chromatin protein HMGB1 to redirect it towards secretion. EMBO J 22:5551–5560

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Lotze MT, Tracey KJ (2005) High-mobility group box 1 protein (HMGB1): nuclear weapon in the immune arsenal. Nat Rev Immunol 5:331–342

    Article  CAS  PubMed  Google Scholar 

  4. Ivanov S, Dragoi AM, Wang X et al (2007) A novel role for HMGB1 in TLR9-mediated inflammatory responses to CpG-DNA. Blood 110:1970–1981

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Rendon-Mitchell B, Ochani M, Li J et al (2003) IFN-gamma induces high mobility group box 1 protein release partly through a TNF-dependent mechanism. J Immunol 170:3890–3897

    Article  CAS  PubMed  Google Scholar 

  6. Tang D, Shi Y, Kang R et al (2007) Hydrogen peroxide stimulates macrophages and monocytes to actively release HMGB1. J Leukoc Biol 81:741–747

    Article  CAS  PubMed  Google Scholar 

  7. Scaffidi P, Misteli T, Bianchi ME (2002) Release of chromatin protein HMGB1 by necrotic cells triggers inflammation. Nature 418:191–195

    Article  CAS  PubMed  Google Scholar 

  8. Wang H, Ward MF, Fan XG et al (2006) Potential role of high mobility group box 1 in viral infectious diseases. Viral Immunol 19:3–9

    Article  PubMed  Google Scholar 

  9. Zhu S, Li W, Ward MF et al (2010) High mobility group box 1 protein as a potential drug target for infection- and injury-elicited inflammation. Inflamm Allergy Drug Targets 9:60–72

    Article  PubMed  PubMed Central  Google Scholar 

  10. Wang H, Ward MF, Sama AE (2009) Novel HMGB1-inhibiting therapeutic agents for experimental sepsis. Shock 32:348–357

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Wang H, Yang H, Tracey KJ (2004) Extracellular role of HMGB1 in inflammation and sepsis. J Intern Med 255:320–331

    Article  CAS  PubMed  Google Scholar 

  12. Wang H, Li W, Goldstein R, Tracey KJ, Sama AE (2007) HMGB1 as a potential therapeutic target. Novartis Found Symp 280:73–85

    CAS  PubMed  Google Scholar 

  13. Wang H, Zhu S, Zhou R et al (2008) Therapeutic potential of HMGB1-targeting agents in sepsis. Expert Rev Mol Med 10:e32

    Article  PubMed  PubMed Central  Google Scholar 

  14. Kang R, Xie Y, Zhang Q et al (2017) Intracellular HMGB1 as a novel tumor suppressor of pancreatic cancer. Cell Res 27:916–932

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Jiao Y, Wang HC, Fan SJ (2007) Growth suppression and radiosensitivity increase by HMGB1 in breast cancer. Acta Pharmacol Sin 28:1957–1967

    Article  CAS  PubMed  Google Scholar 

  16. Liu P, Zhao L, Loos F et al (2018) Epigenetic anticancer agents cause HMGB1 release in vivo. Oncoimmunology 7:e1431090

    Article  PubMed  PubMed Central  Google Scholar 

  17. Wang L, He L, Bao G et al (2016) Ionizing radiation induces HMGB1 cytoplasmic translocation and extracellular release. Guo Ji Fang She Yi Xue He Yi Xue Za Zhi 40:91–99

    PubMed  PubMed Central  Google Scholar 

  18. Bald T, Quast T, Landsberg J et al (2014) Ultraviolet-radiation-induced inflammation promotes angiotropism and metastasis in melanoma. Nature 507:109–113

    Article  CAS  PubMed  Google Scholar 

  19. Kargi A, Demirpence O, Gunduz S et al (2016) Serum levels of HMGB1 have a diagnostic role in metastatic renal cell cancer. Cancer Biomark 17:17–20

    Article  CAS  PubMed  Google Scholar 

  20. Napolitano A, Antoine DJ, Pellegrini L et al (2016) HMGB1 and its hyperacetylated isoform are sensitive and specific serum biomarkers to detect asbestos exposure and to identify mesothelioma patients. Clin Cancer Res 22:3087–3096

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Urbonaviciute V, Furnrohr BG, Weber C et al (2007) Factors masking HMGB1 in human serum and plasma. J Leukoc Biol 81:67–74

    Article  CAS  PubMed  Google Scholar 

  22. Sha Y, Zmijewski J, Xu Z, Abraham E (2008) HMGB1 develops enhanced proinflammatory activity by binding to cytokines. J Immunol 180:2531–2537

    Article  CAS  PubMed  Google Scholar 

  23. Lehner J, Wittwer C, Fersching D et al (2012) Methodological and preanalytical evaluation of an HMGB1 immunoassay. Anticancer Res 32:2059–2062

    CAS  PubMed  Google Scholar 

  24. He RL, Zhou J, Hanson CZ et al (2009) Serum amyloid A induces G-CSF expression and neutrophilia via Toll-like receptor 2. Blood 113:429–437

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Yasuda T, Ueda T, Takeyama Y et al (2006) Significant increase of serum high-mobility group box chromosomal protein 1 levels in patients with severe acute pancreatitis. Pancreas 33:359–363

    Article  CAS  PubMed  Google Scholar 

  26. Gaini S, Pedersen SS, Koldkjaer OG et al (2007) High mobility group box-1 protein in patients with suspected community-acquired infections and sepsis: a prospective study. Crit Care 11:R32

    Article  PubMed  PubMed Central  Google Scholar 

  27. Okazaki K, Kondo M, Kato M et al (2008) Elevation of high-mobility group box 1 concentration in asphyxiated neonates. Neonatology 94:105–109

    Article  CAS  PubMed  Google Scholar 

  28. Karlsson S, Pettila V, Tenhunen J et al (2008) HMGB1 as a predictor of organ dysfunction and outcome in patients with severe sepsis. Intensive Care Med 34(6):1046–1053

    Article  CAS  PubMed  Google Scholar 

  29. Rowe SM, Jackson PL, Liu G et al (2008) Potential role of high-mobility group box 1 in cystic fibrosis airway disease. Am J Respir Crit Care Med 178:822–831

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Yoshizaki A, Komura K, Iwata Y et al (2009) Clinical significance of serum HMGB-1 and sRAGE levels in systemic sclerosis: association with disease severity. J Clin Immunol 29:180–189

    Article  CAS  PubMed  Google Scholar 

  31. Chung HW, Lee SG, Kim H et al (2009) Serum high mobility group box-1 (HMGB1) is closely associated with the clinical and pathologic features of gastric cancer. J Transl Med 7:38. https://doi.org/10.1186/1479-5876-7-38

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  32. Dupire G, Nicaise C, Gangji V, Soyfoo MS (2012) Increased serum levels of high-mobility group box 1 (HMGB1) in primary Sjogren’s syndrome. Scand J Rheumatol 41:120–123

    Article  CAS  PubMed  Google Scholar 

  33. Lee H, Song M, Shin N et al (2012) Diagnostic significance of serum HMGB1 in colorectal carcinomas. PLoS One 7:e34318

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  34. Wang H, Yang H, Czura CJ, Sama AE, Tracey KJ (2001) HMGB1 as a late mediator of lethal systemic inflammation. Am J Respir Crit Care Med 164:1768–1773

    Article  CAS  PubMed  Google Scholar 

  35. Angus DC, Yang L, Kong L et al (2007) Circulating high-mobility group box 1 (HMGB1) concentrations are elevated in both uncomplicated pneumonia and pneumonia with severe sepsis. Crit Care Med 35:1061–1067

    Article  PubMed  Google Scholar 

  36. Kazama H, Ricci JE, Herndon JM et al (2008) Induction of immunological tolerance by apoptotic cells requires caspase-dependent oxidation of high-mobility group box-1 protein. Immunity 29:21–32

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  37. Park JS, Arcaroli J, Yum HK et al (2003) Activation of gene expression in human neutrophils by high mobility group box 1 protein. Am J Physiol Cell Physiol 284:C870–C879

    Article  CAS  PubMed  Google Scholar 

  38. Li W, Li J, Sama AE, Wang H (2013) Carbenoxolone blocks endotoxin-induced PKR activation and HMGB1 release. Mol Med 19:203–211

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  39. Li W, Li J, Ashok M et al (2007) A cardiovascular drug rescues mice from lethal sepsis by selectively attenuating a late-acting proinflammatory mediator, high mobility group box 1. J Immunol 178:3856–3864

    Article  CAS  PubMed  Google Scholar 

  40. Wang H, Liao H, Ochani M et al (2004) Cholinergic agonists inhibit HMGB1 release and improve survival in experimental sepsis. Nat Med 10:1216–1221

    Article  CAS  PubMed  Google Scholar 

  41. Li W, Zhu S, Li J et al (2011) A hepatic protein, fetuin-A, occupies a protective role in lethal systemic inflammation. PLoS One 6:e16945

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  42. Li W, Ashok M, Li J et al (2007) A major ingredient of green tea rescues mice from lethal sepsis partly by inhibiting HMGB1. PLoS One 2:e1153

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  43. Yang H, Ochani M, Li J et al (2004) Reversing established sepsis with antagonists of endogenous high-mobility group box 1. Proc Natl Acad Sci U S A 101:296–301

    Article  CAS  PubMed  Google Scholar 

  44. Manganelli V, Signore M, Pacini I et al (2010) Increased HMGB1 expression and release by mononuclear cells following surgical/anesthesia trauma. Crit Care 14:R197

    Article  PubMed  PubMed Central  Google Scholar 

  45. Zhou Y, Xiong KL, Lin S et al (2010) Elevation of high-mobility group protein box-1 in serum correlates with severity of acute intracerebral hemorrhage. Mediat Inflamm 2010:142458. https://doi.org/10.1155/2010/142458. Epub 2010 Sep 29

    Article  CAS  Google Scholar 

  46. Bruchfeld A, Wendt M, Bratt J et al (2011) High-mobility group box-1 protein (HMGB1) is increased in antineutrophilic cytoplasmatic antibody (ANCA)-associated vasculitis with renal manifestations. Mol Med 17:29–35

    Article  CAS  PubMed  Google Scholar 

  47. Shang GH, Jia CQ, Tian H et al (2009) Serum high mobility group box protein 1 as a clinical marker for non-small cell lung cancer. Respir Med 103:1949–1953

    Article  PubMed  Google Scholar 

  48. Goldstein RS, Gallowitsch-Puerta M, Yang L et al (2006) Elevated high-mobility group box 1 levels in patients with cerebral and myocardial ischemia. Shock 25:571–574

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

Work in the authors’ laboratory was supported by grants from the National Institutes of Health (R01GM063075 and R01AT005076).

Author information

Authors and Affiliations

  1. Laboratory of Emergency Medicine, The Feinstein Institute for Medical Research, Manhasset, NY, USA

    Weiqiang Chen, Guoqiang Bao, Lin Zhao & Haichao Wang

  2. Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Hempstead, NY, USA

    Haichao Wang

  3. The Feinstein Institute for Medical Research, Northwell Health System, Manhasset, NY, USA

    Haichao Wang

Authors
  1. Weiqiang Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Guoqiang Bao
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Lin Zhao
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Haichao Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Haichao Wang .

Editor information

Editors and Affiliations

  1. Department of Biological Sciences, St. John’s University, Queens, NY, USA

    Ivana Vancurova

  2. Department of Biological Sciences, St. John’s University, Queens, NY, USA

    Yan Zhu

Rights and permissions

Reprints and permissions

Copyright information

© 2020 Springer Science+Business Media, LLC, part of Springer Nature

About this protocol

Check for updates. Verify currency and authenticity via CrossMark

Cite this protocol

Chen, W., Bao, G., Zhao, L., Wang, H. (2020). Analysis of Circulating HMGB1 in Human Serum. In: Vancurova, I., Zhu, Y. (eds) Immune Mediators in Cancer. Methods in Molecular Biology, vol 2108. Humana, New York, NY. https://doi.org/10.1007/978-1-0716-0247-8_2

Download citation

  • DOI: https://doi.org/10.1007/978-1-0716-0247-8_2

  • Published:

  • Publisher Name: Humana, New York, NY

  • Print ISBN: 978-1-0716-0246-1

  • Online ISBN: 978-1-0716-0247-8

  • eBook Packages: Springer Protocols

Publish with us

Policies and ethics

Search

Navigation